   |
|
Mark Engel, CEO of Excel Pharmastudies, on clinical trials in China |
| In this interview, Mark discusses how he founded and grew Excel Pharmastudies into one of the leading CRO's in China. Mark also addressed opportunities and challenges for big pharma and biotech looking to conduct clinical trials in China. He specifically touches on chemical vs. biologic products, and the rapidly changing competitive landscape for clinical trials providers in China. |
|
|
Interview with Samantha Du, CEO of Hutchison Medipharma |
| Hutchison Medipharma is Shanghai-based pioneer in new drug discovery. In this interview, Samantha discusses the genesis of Medipharma, the company's leading products, progress in clinical trials, high profile deals with Lilly and others, and the current corporate structure. Samantha also elaborates on the company's patent estate and how Medipharma protects its small molecule, mixture, and extract candidates. |
|
|
Interview with Peter Zhang, CEO of GenePharma |
| This month GBI talked with Peter Zhang, CEO of GenePharma. GenePharma is a leading company in China's RNA industry. Peter touched the process of starting a biotech in China, challenges in financing and reaching overseas markets, and the state of China's RNA research. He also explained the reasons for the company’s move to Suzhou’s nascent BioBay from Shanghai's ZhangJiang high technology park. |
|
|
Interview with XianPing Lu, co-founder and president of Chipscreen Biosciences |
| This month GBI talked XianPing Lu, co-founder and president of Chipscreen Biosciences. Based in Shenzhen, Chipscreen is one of China's true drug discovery pioneers, having developed a platform technology and successfully driving several drug candidates into preclinical and clinical testing. In this interview, Dr. Lu discusses the founding of the company, its expanding pipeline, and the value of partnering with multinationals. He also touches on Chipscreen's plans for an IPO on China’s nascent NASDAQ-like board and strategy for commercialization of its late stage candidates. |
|
|
Interview with Jing Lou, CEO of 3SBio |
| This month, GBI sat down with Jing Lou, the CEO of 3SBio, a Chinese biopharmaceutical company that conducted an IPO on NASDAQ in February of 2007. In this interview, Dr. Lou discussed the company's leading product, a generic EPO, and the status of its other products and candidates. Dr. Lou discussed his plans for 3SBio's IPO cash, the impact of recent regulatory changes on the company's market share and prospects, and expanded on the potential for generic biologics in the European and United States markets. |
|
|
James Wen, CEO of SynCores, on chemical synthesis |
| James Wen, CEO of
SynCores, an emerging chemical synthesis service
provider, discusses his views on industry growth
in China, the evolution of the R&D services
business model, the impact of rising wages and
RMB pressure, and how to move from success based
projects to an FTE model. |
|
|
Vaccines
in China - Patrice Bonzom - China GM, Crucell |
| Patrice Bonzom, General Manager of Crucell in China, discusses China's vaccine industry. Covered in this interview is Crucell's growing presence, thoughts on the market for subsidized and unsubsidized vaccines, the potential of the influenza vaccine market, China's pandemic preparations, and multinationals' options for domestic manufacturing. |
|
|
Life
as a GM of Big Pharma in China |
| Kabir Nath, President of Bristol Myers Squibb in China, expands upon the roles of a GM of a multinational pharma in China and discusses BMS's success with Baraclude. Kabir also shares his thoughts on China's pricing process and discusses big pharma's growth constraints in China's rapidly expanding pharmaceutical market. |
|
|
Starting a Specialty Pharmaceutical Company in China |
| In this interview, Mark Lotter, founder and CEO of NovaMed, shares his experience transitioning from big pharma to a start-up, specialty pharmaceutical company in China. Mark addresses challenges facing pharmaceutical companies, including differences between sales and marketing strategies in China versus Western markets, and discusses the overall outlook of China's evolving market. |
|
|
PE and VC in China's Life Science Industry Part I |
| In this interview,
Arthur covers a lot of ground, hitting venture
capital, private equity, and entrepreneurialism
in China's healthcare and life science industries.
Arthur's experience ranges across a number of
deal types, from early to late stage, and public
offerings. |
|
| PE
and VC in China's Life Science Industry Part II |
| In this interview,
Arthur covers a lot of ground, hitting venture
capital, private equity, and entrepreneurialism
in China's healthcare and life science industries.
Arthur's experience ranges across a number of
deal types, from early to late stage, and public
offerings. |
|
| IP
in China Tony's Top 10 |
| In this interview,
Tony expands upon China's intellectual property
landscape, especially related to biotechnology
and pharmaceuticals. He addresses both systematic
challenges and practical considerations for multinationals,
investors, and China's domestic enterprises. |
|
| IP
in China ᾿Tony Addresses Common IP Questions |
| In this interview,
Tony expands upon China's intellectual property
landscape, especially related to biotechnology
and pharmaceuticals. He addresses both systematic
challenges and practical considerations for multinationals,
investors, and China's domestic enterprises. |
|
| |